Chas Bountra - Podcast Details

Shows

Campus by Times Higher EducationCampus: Knowledge exchange and data management as drivers of research and innovationWhat underpins effective research, knowledge generation and innovation? In this podcast, we hear a world-leading biomedical scientist discuss what constitutes effective knowledge exchange and supports translational research that can, ultimately, result in innovations that change the world for the better. Plus, a data scientist outlines the opportunities and risks associated with the proliferation in, but also greater regulation of, online data and what this could mean for future research. Chas Bountra is pro-vice chancellor for innovation of the University of Oxford – we spoke just a week before the University of Oxford was named as the world’s lead...2024-10-101h 01

OxTalksRetaining World-class Talent in OxfordshireWelcome to OxTalks, powered by OxLEP, the Local Enterprise Partnership for Oxfordshire. OxTalks aims to give you more insight into the great work that OxLEP does, empowering and enabling businesses across Oxfordshire and beyond to add value to their organisation and, crucially, to the communities they serve.In this episode we discuss the following:Some of the world's most-talented people work in the county with a host of globally-significant companies calling Oxfordshire home. Last year alone spin-outs, start-ups and social enterprises from Oxford University Innovation generated over £30 million of income.Many of these p...2023-03-2749 min

The Real Chemistry PodcastBreaking Down Healthcare Industry Barriers: Chas Bountra, PhD, Pro Vice-Chancellor for Innovation & Professor for Translational Medicine, University of Oxford & Jim Weiss, Founder & CEO, Real ChemistryChas Bountra, PhD, Pro Vice-Chancellor for Innovation & Professor for Translational Medicine at the University of Oxford, and Jim Weiss, Founder & CEO of Real Chemistry, join this week’s episode to discuss accelerating healthcare through novel ideas and the importance of collaborating across organizations, industries and countries. 2023-01-0536 min

Innovative Greeks TalksChas Bountra: Ο καθηγητής της Οξφόρδης συζητά για την καινοτομία στην Ιατρική & την κλιματική αλλαγήΟ Chas Bountra είναι καθηγητής Translational Medicine στο Πανεπιστήμιο της Οξφόρδης και ασχολείται με το πώς ένα φάρμακο ξεκινάει από τον... πάγκο του εργαστηρίου μέχρι να φτάσει στους ασθενείς.Πιστεύει ότι οι προκλήσεις που αντιμετωπίζουμε είναι πανανθρώπινες και ότι, μέσω συνεργασιών, θα μπορέσει η ανθρωπότητα να προχωρήσει πολύ γρήγορα και να δώσει λύσεις σε καίρια προβλήματα όπως μακροχρόνιες ασθένειες ή την κλιματική αλλαγή.Στη συζήτηση με τον Μάρκο Βερέμη, αναλύει πώς η τεχνολογία έχει βοηθήσει την Ιατρική να κάνει άλματα προόδου ενώ, παράλληλα, εξηγεί γιατί είναι τόσο δύσκολο να αντιμετωπίσουμε ασθένειες που διαμορφώνονται τόσο από τη γενετική προδιάθεση των ανθρώπων, όσο και από το περιβάλλον που ζούμε.Ευχαριστούμε τη Google για την υποστήριξή της στην παραγωγή της σειράς συζητήσεων Innovative Greeks Talks.Disclaimer: Ο ΣΕΒ προσφέρει την ευκαιρία να ακουστούν οι απόψεις και οι εμπειρίες των προσκεκλημένων στα Innovative Greeks Talks. Οι γνώμες και οι απόψεις που εκφράζονται μέσα σε αυτά είναι προσωπικές και σε καμία περίπτωση δεν απηχούν γνώμες και απόψεις του ΣΕΒ. 2022-12-141h 01

Business LeaderOxford, innovation and the future of the UK economy?The UK has world-leading universities. It is one area where the country really can claim to be world-leading. But Britain’s universities have not been as good as their international rivals at turning brilliant ideas into brilliant businesses. That may be about to change though. The University of Oxford is thinking more than ever before about how to turn its ideas and research into businesses. In this episode of Business Studies we look at how. We speak to three people at the centre of a collaboration between the university and the private sector. They are: Professor Chas Bountra, pro vice-chancellor fo...2022-12-1345 min

Leadership In Extraordinary Times7 Revolutionising healthcare innovation: putting communities firstIn episode seven, leaders from industry, policy-making, academia as well as entrepreneurs discuss working collaboratively to drive community-centred, ‘outside in’ innovation for health. Featuring: Professor Chas Bountra, Pro Vice-Chancellor for Innovation, University of Oxford. Srin Madipalli (@SrinMadipalli), tech entrepreneur and accessibility expert. Maayan Ziv (@maayanziv), CEO, AccessNow. Pēteris Zilgalvis (@PZilgalvis), Head of Unit for Digital Innovation and Blockchain, European Commission. Dr Vreni Schoenenberger, Global Head of Public Affairs, Neuroscience, Novartis. Donna Wa...2021-03-3153 min

Oxford Martin School: Public Lectures and SeminarsHealthcare after the COVID-19 pandemic: the walls are coming downJoin Professor Chas Bountra, Professor of Translational Medicine and Professor Sir Charles Godfray as they discuss how the healthcare system has had to adapt due to the Covid-19 pandemic and what this means in the future.2021-02-0459 min

RPS PharmSci TodayPharmSci Today #16Gino and Sarah talk to Chas Bountra, Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. The first working COVID vaccine could come from Oxford, and Professor Bountra discusses the secret of the city's success in the fight against the pandemic. Hosted on Acast. See acast.com/privacy for more information.2020-07-2320 min

rpharmsRPS PharmSci Today #16Gino and Sarah talk to Chas Bountra, Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford.The first working COVID vaccine could come from Oxford, and Professor Bountra discusses the secret of city's success in the fight against the pandemic.2020-07-2220 min

The Oxford Reproducibility SchoolThe pharmaceutical industry believes that a lot of academic literature is not reproducible. How should we respond?Chas Bountra (University of Oxford) gives a talk for the Oxford Reproducibility School.2017-12-0828 min

Oxford Martin School: Public Lectures and SeminarsWhy do we need to reconstruct drug discovery?Dr Javier Lezaun and Professor Chas Bountra give a talk about drug discovery. Dr Javier Lezaun, Co-Director, Institute for Science, Innovation and Society, Oxford Martin School and James Martin Lecturer in Science and Technology Governance and Professor Chas Bountra, Chief Scientist (SGC), Professor of Translational Medicine, Nuffield Department of Clinical Medicine, University of Oxford 2015-02-171h 27

Lift conferenceChas Bountra - Innovation Through Open Access and Public-private PartnershipChas Bountra is a professor of translational medicine at the University of Oxford as well as Chief Scientist at the Structural Genomic Consortium, a public-private partnership that supports the discovery of new medicines through open access research. Prior to coming back to Oxford, Chas spent many years in the pharmaceutical industry and culminated as Vice President and Head of Biology at GlaxoSmithKline. He was involved in the identification of more than 40 clinical candidates for many gastro-intestinal, inflammatory and neuro-psychiatric diseases. He was involved in the launch and development of the first treatment for Irritable Bowel Syndrome (Alosetron).2014-11-1300 min

Alumni WeekendWhy is Oxford Determined to Change the Way We Discover New Medicines?Chas Bountra, a popular speaker at the recent Meeting Minds: Alumni Weekend in Asia, will explain how Oxford is creating a new ecosystem for drug discovery.2014-10-0743 min

CHI PodcastsStructure-Based Drug Design and Target Validation 2014 | New Targets for Drug DiscoveryCHI recently spoke with Dr. Chas Bountra, Head of the Structural Genomics Consortium (SGC), and Professor of Translational Medicine and an Associate Head of Medical Sciences at the University of Oxford. In this podcast, Dr. Bountra discusses how the SGC is impacting drug discovery and their work on developing novel probes, specifically for epigenetic targets. Dr. Bountra also gives a sneak peek into his keynote lecture joining the Structure-Based Drug Design and Chemical Biology for Target Validation meetings, May 22 in Boston.2014-04-0200 min

NDM Public EngagementScience Oxford Live 2013 - Public EngagementThe Nuffield Department of Medicine recognises that public engagement is vital to educate, inform and build relationships with the community. Our scientists are actively engaging in open discussion, meeting people to debate, listen and learn. Our series of evening lectures at Science Oxford Live, as part of the Healthy Season in spring 2013, was a great success. We are grateful to all of our speakers: Dr Julian Knight (Wellcome Trust Centre for Human Genetics), Professor Tim Key (Cancer Epidemiology Unit), Professor Adrian Hill and Dr Simon Draper (Jenner Institute), Professor Chas Bountra and Professor Stefan Knapp (Structural Genomics Consortium), and Dr...2013-09-1701 min

NDM Public EngagementDrug Discovery: Your questionsHow does medicine work? How are new drugs made? What role does the pharmaceutical industry play? Professors Stefan Knapp and Chas Bountra joined Science Oxford Live in spring 2013 for an evening of Scientists on the sofa, to take your questions. Have you really got a model for how this ought to work? I wanted to comment about the publication of negative findings. Have you been involved? What is your view on this? How quickly do you think it will happen? You spoke about the research institutes closing down; are they closing down in the UK and relocating, or are they...2013-07-1609 min

NDM Public EngagementDrug DiscoveryHow does medicine work? How are new drugs made? What role does the pharmaceutical industry play? Professors Stefan Knapp and Chas Bountra work in the field of drug discovery. They joined Science Oxford talks in spring 2013. Society is increasingly desperate for novel medicine. Most drugs used today were developed more than 40 years ago. With our ageing population, the incidence of diseases such as dementia, cardiovascular disease, and cancer will increase exponentially over the coming years.2013-07-1616 min

NDM Public EngagementDiscovery of new medicines and the future of drug developmentHow does medicine work? How are new drugs made? What role does the pharmaceutical industry play? Professors Stefan Knapp and Chas Bountra work in the field of drug discovery. They joined Science Oxford talks in spring 2013. Over the past 30 to 40 years there have been drastic changes in the way new medicines are developed. Before the 1970s drug development was based on phenotypic assays and 'accidental findings', with an approval process that would often take two to three years to complete. Scientists now have a better understanding of the mechanisms leading to disease development, allowing the selection of 'targets' - regulators...2013-07-1611 min

DiscoveryEnd of Drug DiscoveryWe are in desperate need of new medicines for the major diseases facing us in the 21st Century such as Alzheimer's and obesity. And we are running out of antibiotics that are effective against bacteria that are now resistant to many old varieties. As bringing new and improved drugs to patients becomes more difficult and more expensive - it can take 20 years and around $1 billion to bring a medicine to market - Geoff Watts asks what's gone wrong and what can be done to get new pharmaceutical treatments to patients.Geoff talks to a number of researchers...2012-10-0818 min

FT Science with Clive CooksonCamouflage, prevention and the future of pharmaIn this week's podcast: We return to our science and art feature with author Peter Forbes and his new book – Dazzled and Deceived: Mimicry and Camouflage; we consider the debate surrounding prevention rather than cure with Andrew Thompson from biomedical company Proteus; we look at the future of the pharma industry following the announcement by Pfizer recently that it is to close its research facility in Kent, with Dr Chas Bountra, chief scientist and head of the Structural Genomics Consortium at Oxford University.Presented by Andrew Jack with Diana Garnham.Produced by LJ Filotrani Hosted on Acast. See ac...2011-02-1516 min

Translational MedicineDrug DiscoveryProfessor Chas Bountra explains how new drugs can offer novel treatments for neurodegenerative and gastrointestinal diseases, as well as pain disorders. Professor Chas Bountra is interested in identifying and validating target proteins for drug discovery. Various technologies and strategies have allowed him to progress promising clinical candidates into Phase I, II, III studies, and to market. Drug candidates are first selected by screening compounds capable of binding to a target protein. Those compounds are then tested in various assay systems, healthy volunteers and finally in patients. Academic research excels at defining good target proteins. Pharmaceutical companies then facilitate the transition...2010-12-2005 min

Translational and ClinicalDrug DiscoveryProfessor Chas Bountra explains how new drugs can offer novel treatments for neurodegenerative and gastrointestinal diseases, as well as pain disorders. Professor Chas Bountra is interested in identifying and validating target proteins for drug discovery. Various technologies and strategies have allowed him to progress promising clinical candidates into Phase I, II, III studies, and to market. Drug candidates are first selected by screening compounds capable of binding to a target protein. Those compounds are then tested in various assay systems, healthy volunteers and finally in patients. Academic research excels at defining good target proteins. Pharmaceutical companies then facilitate the transition...2010-12-2000 min